Advanced Cell Technologies' $35m funding lets it play hard to get
This article was originally published in Clinica
Executive Summary
Regenerative medicine company Advanced Cell Technology has secured a $35 million stock purchase commitment from Lincoln Park Capital which its chairman and CEO Gary Rabin described as "the best financing deal of any type that ACT has ever secured in its 18-year history as both a private and public company".